SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is trending after securing a $250 million capital commitment that extends its operational runway to 2028, fueling community debate between those anticipating a major short squeeze as the company shifts to revenue generation, and others worried about continued dilution and fundamental value.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X (CCCX) is a major talking point as Infleqtion, its quantum technology merger target, recently secured a NASA space mission role and a significant U.S. Department of Energy contract, leading many to believe it's severely undervalued compared to other quantum stocks ahead of its anticipated merger and ticker change to INFQ.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Following its recent earnings report, Fiserv is seeing divided community discussion around its perceived deep value and turnaround potential under new leadership, while concerns persist over its debt, shrinking margins, and the broader fintech sector's challenges.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Luxembourg.

Spotify Technology S.A.

Spotify is rallying after a strong earnings report showcased impressive user and subscriber growth alongside improved profitability and optimistic guidance, prompting analyst upgrades and expectations for higher price targets. The community is actively discussing these strategic gains, even as debate continues around recent subscription price increases and competition in the streaming sector.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

Jumia Technologies trends after an earnings report revealed strong revenue and GMV growth, significant cash burn reduction, and a clear path to profitability without needing a capital raise, yet the stock's initial dip has puzzled many long-term investors who view it as the "Amazon of Africa" for an underserved market.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is generating buzz following its latest earnings report, where a substantial 2026 guidance predicting profitability and record membership growth is fueling a bullish narrative. This optimism directly contrasts with a quarterly financial miss that has skeptics questioning the sustainability of its aggressive forward outlook amidst broader healthcare sector uncertainties.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Nektar Therapeutics is trending after reporting strong 52-week maintenance data for its atopic dermatitis drug, rezpegaldesleukin, demonstrating durable efficacy comparable to or exceeding competitors like Dupixent. The community is buzzing about the drug's potential, with many anticipating higher price targets, a significant short squeeze, and the possibility of a big pharma buyout.

Evommune, Inc. is a clinical-stage biotechnology company. It engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pena, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Palo Alto, CA.

Evommune Inc.

Evommune Inc

Evommune is seeing a surge in attention after announcing positive Phase 2a trial results for its atopic dermatitis drug EVO301, sparking a battle between bullish traders anticipating a short squeeze and a skeptical community betting against the rally amid claims of overvaluation.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is trending after reporting strong Q4 earnings that initially sent the stock higher, driven by significant client additions and an upbeat outlook. However, these gains were quickly erased as concerns over increased competition in the observability sector, including recent acquisitions by rivals, are actively weighing on community sentiment.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance (PSKY) is trending as it sweetens its all-cash offer for Warner Bros. Discovery (WBD), increasing financial protections and touting a clearer regulatory path compared to Netflix's (NFLX) bid which faces DOJ scrutiny; the community is also discussing PSKY's recent UFC event viewership amidst calls for improved stock performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Federated Hermes Inc. Has $905,000 Stock Position in Tarsus Pharmaceuticals, Inc. $TARS

Federated Hermes Inc. cut its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 72.3% in the third quarter, according to the company in its most recent Form 13F filing...

Will Declining Medical Customers Affect Cigna's Q4 Earnings?

CI heads into Q4 earnings with rising Evernorth revenues but falling premiums and medical customers, raising questions about the quarter's overall growth outlook.

Lisanti Capital Growth LLC Has $2.56 Million Position in Tarsus Pharmaceuticals, Inc. $TARS

Lisanti Capital Growth LLC cut its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 43.1% in the 3rd quarter, according to the company in its most recent filing with the...

Universal Beteiligungs und Servicegesellschaft mbH Has $5.44 Million Stake in Tarsus Pharmaceuticals, Inc. $TARS

Universal Beteiligungs und Servicegesellschaft mbH increased its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 77.0% in the third quarter, according to the company...

Down 16.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Tarsus Pharmaceuticals (TARS)

Tarsus Pharmaceuticals (TARS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

SG Americas Securities LLC Sells 27,833 Shares of Tarsus Pharmaceuticals, Inc. $TARS

SG Americas Securities LLC lessened its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 81.8% during the 3rd quarter, according to its most recent 13F filing with the SEC. The...

Relative Strength Alert For Tarsus Pharmaceuticals

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a...

BMRN or TARS: Which Is the Better Value Stock Right Now?

BMRN vs. TARS: Which Stock Is the Better Value Option?

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) have received a consensus rating of "Moderate Buy" from the nine research firms that are presently covering the company...

Tarsus Pharmaceuticals (NASDAQ:TARS) CEO Sells $495,060.00 in Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) CEO Bobak Azamian sold 6,000 shares of the business's stock in a transaction dated Wednesday, December 24th. The stock was sold at an...

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. It is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.

Tarsus Pharmaceuticals Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $SHOP earnings on Wednesday?

Current Price	$65.82
Prev Close	$65.50
Open	$65.50
Dividend Yield	0.00%
50-Day Moving Average	$75.74
Beta	0.73
Avg. Volume	541,035.80
PE Ratio	-32.53

52-Week High	$85.25
52-Week Low	$38.51
Market Capitalization	$2.78B
EPS (Annual)	-$3.07
Price to Book	8.30
Revenue Per Employee	$566,417.96
Enterprise Value/EBITDA	N/A

TARS
Tarsus Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TARS News

TARSTarsus Pharmaceuticals Inc